Sangamo Therapeutics Reports Positive Phase 1/2 STAAR Data for Fabry Gene Therapy, BLA Submission Underway

summarizeSummary

Sangamo Therapeutics reported positive clinical data for its Fabry disease gene therapy, ST-920, from the Phase 1/2 STAAR study, with the FDA agreeing to an Accelerated Approval pathway and a BLA submission already initiated.

check_boxKey Events · Product Development and Regulatory · SGMO

• Positive Clinical Data for Fabry Gene Therapy

  Sangamo Therapeutics presented positive clinical data from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920) for Fabry disease, showing a favorable safety profile and sustained therapeutic effects.

• FDA Accelerated Approval Pathway Confirmed

  The U.S. Food and Drug Administration (FDA) agreed that data from the Phase 1/2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using mean annualized eGFR slope at 52 weeks as an intermediate clinical endpoint.

• Biologics License Application (BLA) Submission Initiated

  The company initiated a rolling submission of a Biologics License Application (BLA) to the FDA in December 2025, seeking approval for isaralgagene civaparvovec under the Accelerated Approval pathway.

• Robust Efficacy and Safety Profile

  The therapy was generally well-tolerated, with most adverse events being mild or moderate. Patients showed sustained normal to supraphysiological levels of α-Gal A activity, reduction/stabilization of lyso-Gb3, positive mean annualized eGFR slopes, stable cardiac function, and significant improvements in quality of life and GI symptoms.

auto_awesomeAnalysis · SGMO · Life Sciences

This 8-K filing is highly significant as Sangamo Therapeutics announced comprehensive positive clinical data from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The data, presented at the 22nd Annual WORLD Symposium, demonstrates the therapy's favorable safety profile, sustained therapeutic activity, and positive impact on key disease markers and patient quality of life. Crucially, the FDA has agreed to an Accelerated Approval pathway using eGFR slope as an intermediate clinical endpoint, and the company initiated a rolling Biologics License Application (BLA) submission in December 2025. This combination of strong clinical results, a clear regulatory path, and an active BLA submission significantly de-risks the program and represents a major step towards potential market approval, which is transformational for a life sciences company of this size.